Compare Novo Nordisk A/S (NVO) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Ryanair Holdings plc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Ryanair Holdings plc trades at $58.99 (market cap $29.31B). The key difference: Novo Nordisk A/S is far larger — about 7.5× Ryanair Holdings plc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RYAAY | |
|---|---|---|
Market Cap | $220.53B | $29.31B |
Sector | Health | Industrials |
52-Week High | $71.70 | $73.82 |
52-Week Low | $35.29 | $53.24 |
Enterprise Value | $239.49B | $26.33B |
Dividend Yield | 3.63% | 1.68% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
